A2 Review article, Literature review, Systematic review
Engineered bacteriophages : A panacea against pathogenic and drug resistant bacteria (2024)

Kakkar, A., Kandwal, G., Nayak, T., Jaiswal, L. K., Srivastava, A., & Gupta, A. (2024). Engineered bacteriophages : A panacea against pathogenic and drug resistant bacteria. Heliyon, 10(14), Article e34333. https://doi.org/10.1016/j.heliyon.2024.e34333

JYU authors or editors

Publication details

All authors or editors: Kakkar, Anuja; Kandwal, Garima; Nayak, Tanmayee; Jaiswal, Lav Kumar; Srivastava, Amit; Gupta, Ankush

Journal or series: Heliyon

ISSN: 2405-8440

eISSN: 2405-8440

Publication year: 2024

Publication date: 09/07/2024

Volume: 10

Issue number: 14

Article number: e34333

Publisher: Elsevier

Publication country: United Kingdom

Publication language: English

DOI: https://doi.org/10.1016/j.heliyon.2024.e34333

Publication open access: Openly available

Publication channel open access: Open Access channel

Publication is parallel published (JYX): https://jyx.jyu.fi/handle/123456789/96644

Abstract

Antimicrobial resistance (AMR) is a major global concern; antibiotics and other regular treatment methods have failed to overcome the increasing number of infectious diseases. Bacteriophages (phages) are viruses that specifically target/kill bacterial hosts without affecting other human microbiome. Phage therapy provides optimism in the current global healthcare scenario with a long history of its applications in humans that has now reached various clinical trials. Phages in clinical trials have specific requirements of being exclusively lytic, free from toxic genes with an enhanced host range that adds an advantage to this requisite. This review explains in detail the various phage engineering methods and their potential applications in therapy. To make phages more efficient, engineering has been attempted using techniques like conventional homologous recombination, Bacteriophage Recombineering of Electroporated DNA (BRED), clustered regularly interspaced short palindromic repeats (CRISPR)-Cas, CRISPY BRED/Bacteriophage Recombineering with Infectious Particles (BRIP), chemically accelerated viral evolution (CAVE), and phage genome rebooting. Phages are administered in cocktail form in combination with antibiotics, vaccines, and purified proteins, such as endolysins. Thus, phage therapy is proving to be a better alternative for treating life-threatening infections, with more specificity and fewer detrimental consequences.

Keywords: antibiotic resistance; antimicrobial compounds; pathogens; microbes; viruses; bacteriophages; phage therapy; gene technology

Free keywords: antimicrobial resistance; phage engineering; endolysins; phage therapy

Contributing organizations

Ministry reporting: Yes

VIRTA submission year: 2024

Preliminary JUFO rating: 1